110 related articles for article (PubMed ID: 9432042)
1. A population-based registry on paraproteinaemia in The Netherlands. Comprehensive Cancer Centre West, Leiden, The Netherlands.
Ong F; Hermans J; Noordijk EM; Wijermans PW; Seelen PJ; de Kieviet W; Gerrits WB; Kluin PM; Kluin-Nelemans JC
Br J Haematol; 1997 Dec; 99(4):914-20. PubMed ID: 9432042
[TBL] [Abstract][Full Text] [Related]
2. [The risk of a multiple myeloma in patients with paraproteinemia: a myeloma risk score developed in the region of the Comprehensive Cancer Center West].
Schaar CG; Ong F; Snijder S; Wijermans PW; Franck PF; Kluin-Nelemans JC
Ned Tijdschr Geneeskd; 1998 Jul; 142(28):1591-5. PubMed ID: 9763839
[TBL] [Abstract][Full Text] [Related]
3. Polyneuropathy in paraproteinaemia.
Meier C
J Neurol; 1985; 232(4):204-14. PubMed ID: 2995596
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal gammopathy of undetermined significance (MGUS)-31 year follow up of a community study.
Colls BM
Aust N Z J Med; 1999 Aug; 29(4):500-4. PubMed ID: 10868527
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal gammopathy of unknown significance and malignant paraproteinemia in Hong Kong.
Lolin YI; Chow J; Wickham NW
Am J Clin Pathol; 1996 Oct; 106(4):449-56. PubMed ID: 8853031
[TBL] [Abstract][Full Text] [Related]
6. Management of paraproteinaemia.
Cook L; Macdonald DH
Postgrad Med J; 2007 Apr; 83(978):217-23. PubMed ID: 17403946
[TBL] [Abstract][Full Text] [Related]
7. [Epidemiology of monoclonal gammopathy in a general hospital and a university internal medicine department].
Decaux O; Rodon P; Ruelland A; Estepa L; Leblay R; Grosbois B
Rev Med Interne; 2007 Oct; 28(10):670-6. PubMed ID: 17566610
[TBL] [Abstract][Full Text] [Related]
8. Fracture risk in patients with monoclonal gammopathy of undetermined significance.
Gregersen H; Jensen P; Gislum M; Jørgensen B; Sørensen HT; Nørgaard M
Br J Haematol; 2006 Oct; 135(1):62-7. PubMed ID: 16925792
[TBL] [Abstract][Full Text] [Related]
9. Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation.
Brozova L; Schwarz D; Snabl I; Kalina J; Pavlickova B; Komenda M; Jarkovský J; Němec P; Horinek D; Stefanikova Z; Pour L; Hájek R; Maisnar V
Klin Onkol; 2017; 30(Supplementum2):43-50. PubMed ID: 28903570
[TBL] [Abstract][Full Text] [Related]
10. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgM-MGUS neuropathies are different than IgG-MGUS.
Suarez GA; Kelly JJ
Neurology; 1993 Jul; 43(7):1304-8. PubMed ID: 8327128
[TBL] [Abstract][Full Text] [Related]
11. The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance.
Gregersen H; Madsen KM; Sørensen HT; Schønheyder HC; Ibsen JS; Dahlerup JF
Eur J Haematol; 1998 Aug; 61(2):140-4. PubMed ID: 9714528
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal gammopathy of undetermined significance.
Kyle RA; Rajkumar SV
Clin Lymphoma Myeloma; 2005 Sep; 6(2):102-14. PubMed ID: 16231848
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal gammopathies and malignancies in patients with chronic urticaria.
Karakelides M; Monson KL; Volcheck GW; Weiler CR
Int J Dermatol; 2006 Sep; 45(9):1032-8. PubMed ID: 16961504
[TBL] [Abstract][Full Text] [Related]
15. Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.
Bergin K; Moore E; McQuilten Z; Wood E; Augustson B; Blacklock H; Ho J; Horvath N; King T; McNeil J; Mollee P; Quach H; Reid CM; Rosengarten B; Walker P; Spencer A
BMC Med Res Methodol; 2016 Nov; 16(1):151. PubMed ID: 27829380
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
17. Laboratory and clinical characterization of monoclonal gammopathy in Taiwanese.
Lee LN; Jan IS; Tien HF; Lin JS; Lo SC; Cheng WC
J Formos Med Assoc; 2002 Feb; 101(2):91-7. PubMed ID: 12099210
[TBL] [Abstract][Full Text] [Related]
18. [Skin disorders associated with monoclonal gammopathies].
Houtman CJ; Genders RE; von dem Borne PA; Vermeer MH
Ned Tijdschr Geneeskd; 2014; 158():A6717. PubMed ID: 24780569
[TBL] [Abstract][Full Text] [Related]
19. Use of leucocyte alkaline phosphatase (LAP) score in differentiating malignant from benign paraproteinaemias.
Majumdar G; Hunt M; Singh AK
J Clin Pathol; 1991 Jul; 44(7):606-7. PubMed ID: 1713223
[TBL] [Abstract][Full Text] [Related]
20. Serum interleukin-6 has no discriminatory role in paraproteinaemia nor a prognostic role in multiple myeloma.
Schaar CG; Kaiser U; Snijder S; Ong F; Hermans J; Franck PF; Kluin-Nelemans JC
Br J Haematol; 1999 Oct; 107(1):132-8. PubMed ID: 10520033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
